Investor Relations

investors hero woman and man in a meeting

Corporate Profile

Allena Pharmaceuticals is a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases. Allena is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Scroll to Top